HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 1, 773-781, January 5, 2007

This Article Full Text Full Text (PDF) All Versions of this Article: 282/1/773    most recent M606862200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yu, L.-G. Articles by Rhodes, J. M. Search for Related Content PubMed PubMed Citation Articles by Yu, L.-G. Articles by Rhodes, J. M. Social Bookmarking                      What's this?

Galectin-3 Interaction with Thomsen-Friedenreich Disaccharide on Cancer-associated MUC1 Causes Increased Cancer Cell Endothelial Adhesion^*

Lu-Gang Yu¹, Nigel Andrews, Qicheng Zhao, Daniel McKean, Jennifer F. Williams, Lucy J. Connor, Oleg V. Gerasimenko, John Hilkens^¶, Jun Hirabayashi^||, Kenichi Kasai^||, and Jonathan M. Rhodes

From the Henry Wellcome Laboratory of Molecular and Cellular Gastroenterology, School of Clinical Science and the Physiological Laboratory, School of Biomedical Science, University of Liverpool, Liverpool L69 3BX, United Kingdom, the ^¶Division of Tumour Biology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands, and the ^||Department of Biological Chemistry, Teikyo University, Kanagawa 199-0195, Japan

Patients with metastatic cancer commonly have increased serum galectin-3 concentrations, but it is not known whether this has any functional implications for cancer progression. We report that MUC1, a large transmembrane mucin protein that is overexpressed and aberrantly glycosylated in epithelial cancer, is a natural ligand for galectin-3. Recombinant galectin-3 at concentrations (0.2-1.0 µg/ml) similar to those found in the sera of patients with metastatic cancer increased adhesion of MUC1-expressing human breast (ZR-75-1) and colon (HT29-5F7) cancer cells to human umbilical vein endothelial cells (HUVEC) by 111% (111 ± 21%, mean ± S.D.) and 93% (93 ± 17%), respectively. Recombinant galectin-3 also increased adhesion to HUVEC of MUC1 transfected HCA1.7+ human breast epithelial cells that express MUC1 bearing the oncofetal Thomsen-Friedenreich antigen (Gal1,3 GalNAc- (TF)) but did not affect adhesion of MUC1-negative HCA1.7-cells. MUC1-transfected, Ras-transformed, canine kidney epithelial-like (MDE9.2+) cells, bearing MUC1 that predominantly carries sialyl-TF, only demonstrated an adhesive response to galectin-3 after sialidase pretreatment. Furthermore, galectin-3-mediated adhesion of HCA1.7+ to HUVEC was reduced by O-glycanase pretreatment of the cells to remove TF. Recombinant galectin-3 caused focal disappearance of cell surface MUC1 in HCA1.7+ cells, suggesting clustering of MUC1. Co-incubation with antibodies against E-Selectin or CD44H, but not integrin-1, ICAM-1 or VCAM-1, largely abolished the epithelial cell adhesion to HUVEC induced by galectin-3. Thus, galectin-3, by interacting with cancer-associated MUC1 via TF, promotes cancer cell adhesion to endothelium by revealing epithelial adhesion molecules that are otherwise concealed by MUC1. This suggests a critical role for circulating galectin-3 in cancer metastasis and highlights the functional importance of altered cell surface glycosylation in cancer progression.

Received for publication, July 19, 2006 , and in revised form, November 1, 2006.

^* This work was supported by Mizutani Foundation for Glycoscience Grant 040002 (to L.-G. Y. and J. M. R.), Royal Society Grant 21/2768 (to L.-G. Y.), and Cancer Research UK Grant C7596 (to L.-G. Y.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: The Henry Wellcome Laboratory, School of Clinical Science, University of Liverpool, Liverpool L69 3BX, United Kingdom. Tel.: 44-151-7946820; Fax: 44-151-7946825; E-mail: lgyu{at}liv.ac.uk.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Yue, I. J. Goldstein, M. A. Hollingsworth, K. Kaul, R. E. Brand, and B. B. Haab The Prevalence and Nature of Glycan Alterations on Specific Proteins in Pancreatic Cancer Patients Revealed Using Antibody-Lectin Sandwich Arrays Mol. Cell. Proteomics, July 1, 2009; 8(7): 1697 - 1707. [Abstract] [Full Text] [PDF]

				L. V Norling, M. Perretti, and D. Cooper Endogenous galectins and the control of the host inflammatory response J. Endocrinol., May 1, 2009; 201(2): 169 - 184. [Abstract] [Full Text] [PDF]

				G. Patsos, V. Hebbe-Viton, C. Robbe-Masselot, D. Masselot, R. S. Martin, R. Greenwood, C. Paraskeva, A. Klein, M. Graessmann, J. C. Michalski, et al. O-Glycan inhibitors generate aryl-glycans, induce apoptosis and lead to growth inhibition in colorectal cancer cell lines Glycobiology, April 1, 2009; 19(4): 382 - 398. [Abstract] [Full Text] [PDF]

				S. J Storr, L. Royle, C. J Chapman, U. M A. Hamid, J. F Robertson, A. Murray, R. A Dwek, and P. M Rudd The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum Glycobiology, June 1, 2008; 18(6): 456 - 462. [Abstract] [Full Text] [PDF]

				C. Cederfur, E. Salomonsson, J. Nilsson, A. Halim, C. T Oberg, G. Larson, U. J Nilsson, and H. Leffler Different affinity of galectins for human serum glycoproteins: Galectin-3 binds many protease inhibitors and acute phase proteins Glycobiology, May 1, 2008; 18(5): 384 - 394. [Abstract] [Full Text] [PDF]

				V. L. J. L. Thijssen, F. Poirier, L. G. Baum, and A. W. Griffioen Galectins in the tumor endothelium: opportunities for combined cancer therapy Blood, October 15, 2007; 110(8): 2819 - 2827. [Abstract] [Full Text] [PDF]

				T. K. Dam, T. A. Gerken, B. S. Cavada, K. S. Nascimento, T. R. Moura, and C. F. Brewer Binding Studies of {alpha}-GalNAc-specific Lectins to the {alpha}-GalNAc (Tn-antigen) Form of Porcine Submaxillary Mucin and Its Smaller Fragments J. Biol. Chem., September 21, 2007; 282(38): 28256 - 28263. [Abstract] [Full Text] [PDF]